Prevention and management of cardiotoxicity from antineoplastic therapy

Asher Chanan-Khan, Sridhar Srinivasan, Myron S. Czuczman

Research output: Contribution to journalReview article

35 Scopus citations

Abstract

Cardiotoxicity is a major side effect of various antineoplastic agents, particularly the anthracyclines. Recently, some of the newer drugs and biologic agents that have been introduced into cancer therapeutics also have been shown to have potential cardiotoxic effects. The spectrum of cardiac side effects varies with the antineoplastic agent, dose, and schedule used. Important risk factors associated with cardiotoxicity are cumulative dose, infusion schedule, and pre-existing cardiac disease. This review focuses on the various adverse cardiovascular events associated with antineoplastic agents, what to anticipate, how to recognize the toxicity, how to prevent and minimize the cardiac side effects, and how to manage the full-blown toxicity if and when it occurs.

Original languageEnglish (US)
Pages (from-to)251-256
Number of pages6
JournalJournal of Supportive Oncology
Volume2
Issue number3
StatePublished - May 1 2004

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Prevention and management of cardiotoxicity from antineoplastic therapy'. Together they form a unique fingerprint.

  • Cite this